Skip to main content
. 2015 Jan 22;7:11–17. doi: 10.2147/CPAA.S73472

Table 4.

Number of subjects who experienced adverse events, regardless of study drug relationship (safety population, N=22)

Adverse event, n (%) All subjects (N=22)
Total 12 (54.5)
Headache 6 (27.3)
Dry skin 2 (9.1)
Myalgia 2 (9.1)
Nasopharyngitis 2 (9.1)
Nausea 2 (9.1)
Diarrhea 1 (4.5)
Dizziness 1 (4.5)
Erythema 1 (4.5)
Oral herpes 1 (4.5)
Phlebitis 1 (4.5)
Rhinitis 1 (4.5)
Vaginal hemorrhage 1 (4.5)
Vomiting 1 (4.5)

Note: All adverse events were grade 1 or 2.